Tyrosine kinase inhibitor-induced immune hemolytic anemia; three different drugs in three separate cases

• Published in: Journal of oncology pharmacy practice 2024-01, Vol.30 (1), p.215-219
• Main Authors: Güzel, Halil Göksel, Kıvrak Salim, Derya
• Format: Article
• Language: English
• Subjects: Anemia; Anemia, Hemolytic - drug therapy; Axitinib - therapeutic use; Carcinoma, Renal Cell - drug therapy; Case reports; Complement component C3d; Enzyme inhibitors; Humans; Immune hemolytic anemia; Immunosuppressive agents; Indazoles; Kidney Neoplasms - drug therapy; Protein Kinase Inhibitors - adverse effects; Pyrimidines; Renal cell carcinoma; Soft tissue sarcoma; Solid tumors; Sulfonamides; Sunitinib - adverse effects; Tyrosine Kinase Inhibitors
• ISSN: 1078-1552; 1477-092X
• DOI: 10.1177/10781552231202530

Introduction Molecular multitargeted small tyrosine kinase inhibitory (TKI) agents such as axitinib, sunitinib and pazopanib are commonly used in several types of solid tumors. Anemia is not a rare effect of these drugs which may occur at all grades. However, drug-induced immune hemolytic anemia (IHA), a very rare condition is distinctive from other types of anemia with its specific mechanism and management strategy. Case Reports We reported three different TKI-induced IHA cases that occurred due to axitinib, sunitinib, and pazopanib, respectively. The first two cases were diagnosed with renal cell carcinoma and the last one was diagnosed with soft tissue sarcoma. They all presented with the characteristic symptoms of anemia and hemolysis. All the cases were detected positive for the complement C3d direct antiglobulin (direct coombs) test. Management and Outcomes Discontinuation of the causative drug and 1 mg/kg/day dose of corticosteroid treatment were able to control IHA in all three cases. Excluding the other factors of IHA and an evident laboratory and clinical benefit after withholding the TKI led to the diagnosis of TKI-related IHA in each case. Discussion TKIs are relatively new in clinical practice and are being used for more indications and in more patients. To our knowledge#these three cases are unique in terms of axitinib#sunitinib#and pazopanib-related IHA.